Ohio Living

Founded in 1922, Ohio Living is the largest and most experienced not-for-profit provider of life plan communities and services in Ohio. With headquarters in Columbus, Ohio Living serves more than 90,000 people annually through its wholly owned subsidiaries Ohio Living Communities, Ohio Living Home Health & Hospice and Ohio Living Foundation.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

IMARA ANNOUNCES PRIMARY ENDPOINT CHANGE IN THE ARDENT PHASE 2B CLINICAL TRIAL OF TOVINONTRINE (IMR-687) IN SICKLE CELL DISEASE

Imara | November 22, 2021

news image

Imara Inc. a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA). Imara requested f...

Read More

LOGICBIO ROCKED BY FDA CLINICAL HOLD ON GENOME EDITING TRIAL

FierceBiotech | February 11, 2020

news image

The FDA has placed a clinical hold on LogicBio Therapeutics’ planned genome editing trial. LogicBio wants to trial the therapy in methylmalonic acidemia (MMA) patients aged two years and up but has run into resistance at the FDA. Details of the nature of the regulatory resistance and how soon it is likely to be resolved are scarce. LogicBio provided scant information in its statement to disclose the FDA clinical hold. According to analysts at Jefferies who spoke to management at LogicBio, ...

Read More

INDUSTRIAL IMPACT

BIONTECH AND MEDIGENE ANNOUNCE GLOBAL COLLABORATION TO ADVANCE T CELL RECEPTOR IMMUNOTHERAPIES AGAINST CANCER

BioNTech SE | February 22, 2022

news image

BioNTech SE and Medigene AG a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years. Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech. Medigene&rsqu...

Read More

EMERGENT BIOSOLUTIONS ANNOUNCES INITIATION OF PHASE 3 CINICAL TRIAL OF HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN TO TREAT COVID-19 PATIENTS

Emergent BioSolutions | October 09, 2020

news image

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initia...

Read More
news image

CELL AND GENE THERAPY

IMARA ANNOUNCES PRIMARY ENDPOINT CHANGE IN THE ARDENT PHASE 2B CLINICAL TRIAL OF TOVINONTRINE (IMR-687) IN SICKLE CELL DISEASE

Imara | November 22, 2021

Imara Inc. a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA). Imara requested f...

Read More
news image

LOGICBIO ROCKED BY FDA CLINICAL HOLD ON GENOME EDITING TRIAL

FierceBiotech | February 11, 2020

The FDA has placed a clinical hold on LogicBio Therapeutics’ planned genome editing trial. LogicBio wants to trial the therapy in methylmalonic acidemia (MMA) patients aged two years and up but has run into resistance at the FDA. Details of the nature of the regulatory resistance and how soon it is likely to be resolved are scarce. LogicBio provided scant information in its statement to disclose the FDA clinical hold. According to analysts at Jefferies who spoke to management at LogicBio, ...

Read More
news image

INDUSTRIAL IMPACT

BIONTECH AND MEDIGENE ANNOUNCE GLOBAL COLLABORATION TO ADVANCE T CELL RECEPTOR IMMUNOTHERAPIES AGAINST CANCER

BioNTech SE | February 22, 2022

BioNTech SE and Medigene AG a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years. Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech. Medigene&rsqu...

Read More
news image

EMERGENT BIOSOLUTIONS ANNOUNCES INITIATION OF PHASE 3 CINICAL TRIAL OF HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN TO TREAT COVID-19 PATIENTS

Emergent BioSolutions | October 09, 2020

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initia...

Read More